EP1140969A4 - Fragmente des wachstumsfaktors für bindegewebe und verfahren und anwendungen davon - Google Patents

Fragmente des wachstumsfaktors für bindegewebe und verfahren und anwendungen davon

Info

Publication number
EP1140969A4
EP1140969A4 EP99965256A EP99965256A EP1140969A4 EP 1140969 A4 EP1140969 A4 EP 1140969A4 EP 99965256 A EP99965256 A EP 99965256A EP 99965256 A EP99965256 A EP 99965256A EP 1140969 A4 EP1140969 A4 EP 1140969A4
Authority
EP
European Patent Office
Prior art keywords
methods
ctgf
growth factor
connective tissue
tissue growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99965256A
Other languages
English (en)
French (fr)
Other versions
EP1140969B1 (de
EP1140969A1 (de
Inventor
Gary R Grotendorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Original Assignee
University of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami filed Critical University of Miami
Publication of EP1140969A1 publication Critical patent/EP1140969A1/de
Publication of EP1140969A4 publication Critical patent/EP1140969A4/de
Application granted granted Critical
Publication of EP1140969B1 publication Critical patent/EP1140969B1/de
Priority to CY20071101018T priority Critical patent/CY1108860T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
EP99965256A 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon Expired - Lifetime EP1140969B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CY20071101018T CY1108860T1 (el) 1998-12-14 2007-07-31 Θραυσματα αυξητικου παραγοντα συνδετικου ιστου και μεθοδοι και χρησεις τους

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11224198P 1998-12-14 1998-12-14
US11224098P 1998-12-14 1998-12-14
US112240P 1998-12-14
US112241P 1998-12-14
PCT/US1999/029652 WO2000035936A1 (en) 1998-12-14 1999-12-14 Connective tissue growth factor fragments and methods and uses thereof

Publications (3)

Publication Number Publication Date
EP1140969A1 EP1140969A1 (de) 2001-10-10
EP1140969A4 true EP1140969A4 (de) 2003-07-23
EP1140969B1 EP1140969B1 (de) 2007-06-13

Family

ID=26809725

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99965256A Expired - Lifetime EP1140969B1 (de) 1998-12-14 1999-12-14 Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon
EP99966224A Expired - Lifetime EP1140964B1 (de) 1998-12-14 1999-12-14 Fragment des "connective tissue growth factor" (ctgf)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP99966224A Expired - Lifetime EP1140964B1 (de) 1998-12-14 1999-12-14 Fragment des "connective tissue growth factor" (ctgf)

Country Status (16)

Country Link
US (3) US6492129B1 (de)
EP (2) EP1140969B1 (de)
JP (2) JP4634614B2 (de)
KR (2) KR100664625B1 (de)
CN (3) CN1187370C (de)
AT (2) ATE391724T1 (de)
AU (3) AU773278B2 (de)
CA (2) CA2354422A1 (de)
CY (1) CY1108860T1 (de)
DE (2) DE69938507T2 (de)
DK (1) DK1140969T3 (de)
ES (2) ES2304811T3 (de)
HK (2) HK1041268B (de)
MX (1) MXPA01005949A (de)
PT (1) PT1140969E (de)
WO (2) WO2000035936A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
EP0804562B1 (de) 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Bindegewebswachstumsfaktor-2
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
EP1373299A4 (de) * 2000-07-11 2005-01-19 Human Genome Sciences Inc Bindegewebs-wachstumsfaktor-2
EP1434993B1 (de) * 2001-09-18 2013-04-24 Fibrogen, Inc. Verfahren zum testen des bindegewebe-wachstumsfaktors
CN1604783A (zh) * 2001-10-26 2005-04-06 里伯药品公司 通过rna干扰治疗纤维化疾病的药物
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CN1602207A (zh) * 2001-12-11 2005-03-30 法布罗根股份有限公司 抑制眼病理过程的方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
EP1687410A4 (de) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Für das nieren-targeting optimierte antisense-oligonukleotide
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
DE602005008013D1 (de) 2004-02-11 2008-08-21 Fibrogen Inc Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
CN1929861B (zh) * 2004-02-11 2010-12-29 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
US20050271670A1 (en) 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
WO2005116194A1 (ja) * 2004-05-25 2005-12-08 Riken 試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (de) * 2005-02-22 2006-08-23 Boehringer Ingelheim International GmbH Transgenes Tier als Modell für Lungenkrankheiten des Menschen
NZ563493A (en) 2005-05-05 2010-10-29 Fibrogen Inc Use of an anti-CTGF agent for the treatment of a vascular dysfunction in a patient
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
WO2008027288A2 (en) 2006-08-30 2008-03-06 The Trustees Of Columbia University In The City Of New York Treatment for craniosynostosis by growth factor delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8617877B2 (en) * 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
KR101877698B1 (ko) * 2008-08-25 2018-07-12 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010027830A2 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
WO2011002525A1 (en) 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
MX365647B (es) * 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
JP6040943B2 (ja) * 2011-12-22 2016-12-07 アステラス製薬株式会社 新規抗ヒトｃｔｇｆ抗体
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
US9132171B2 (en) 2012-05-23 2015-09-15 Wisconsin Alumni Research Foundation Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
CA2986926A1 (en) 2015-06-15 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) * 2020-04-13 2020-07-17 西南大学 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038168A1 (en) * 1995-06-02 1996-12-05 Grotendorst Gary R Methods and uses of connective tissue growth factor as an induction agent
US5780263A (en) * 1995-06-05 1998-07-14 Human Genome Sciences, Inc. Human CCN-like growth factor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392024A (en) * 1888-10-30 Jjett
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP0804562B1 (de) * 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Bindegewebswachstumsfaktor-2
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en) 1995-06-01 1997-11-18 The University Of Medicine And Dentistry Of New Jersey Long term maintenance of lymphocytes in vitro
EP0827742A1 (de) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Verwendung von Histondeacetylasehemmern zur Behandlung von Fibrose oder Zirrhose
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
AU1682699A (en) * 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO1999042583A1 (en) * 1998-02-20 1999-08-26 Zymogenetics, Inc. Connective tissue growth factor homologs
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038168A1 (en) * 1995-06-02 1996-12-05 Grotendorst Gary R Methods and uses of connective tissue growth factor as an induction agent
US5780263A (en) * 1995-06-05 1998-07-14 Human Genome Sciences, Inc. Human CCN-like growth factor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 14 July 1998 (1998-07-14), HASTINGS & ADAMS: "Human CCN-like growth factor", XP002238117, Database accession no. AAC91583 *
DATABASE EMBL [online] EBI; 31 May 1997 (1997-05-31), GROTENDORST GR: "Connective tissue growth factor composition", XP002238116, Database accession no. AAW12694 *
FRAZIER KEN ET AL: "Stimulation of fibroblast cell growth, matrix production and granulation tissue formation by connective tissue growth factor.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 107, no. 3, 1996, pages 404 - 411, XP009009184, ISSN: 0022-202X *
SHIMO TSUYOSHI ET AL: "Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells.", JOURNAL OF BIOCHEMISTRY (TOKYO), vol. 124, no. 1, July 1998 (1998-07-01), pages 130 - 140, XP009009314, ISSN: 0021-924X *
STEFFEN C L ET AL: "CHARACTERIZATION OF CELL-ASSOCIATED AND SOLUBLE FORMS OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) PRODUCED BY FIBROBLAST CELLS IN VITRO", GROWTH FACTORS, HARWOOD ACADEMIC PUBLISHERS GMBH, XX, vol. 15, no. 3, 1998, pages 199 - 213, XP001000244, ISSN: 0897-7194 *

Also Published As

Publication number Publication date
KR20010101207A (ko) 2001-11-14
ES2288321T3 (es) 2008-01-01
DE69938507T2 (de) 2009-06-10
CN1334819A (zh) 2002-02-06
MXPA01005949A (es) 2002-09-18
US6492129B1 (en) 2002-12-10
KR20010101194A (ko) 2001-11-14
DE69936315T2 (de) 2008-02-14
EP1140969B1 (de) 2007-06-13
DE69936315D1 (de) 2007-07-26
US20030180300A1 (en) 2003-09-25
AU2004205171B2 (en) 2007-08-09
JP2002532084A (ja) 2002-10-02
CN1187370C (zh) 2005-02-02
US20100190838A1 (en) 2010-07-29
AU775391B2 (en) 2004-07-29
WO2000035939A2 (en) 2000-06-22
HK1041005A1 (en) 2002-06-28
ATE364617T1 (de) 2007-07-15
EP1140969A1 (de) 2001-10-10
DE69938507D1 (en) 2008-05-21
KR100664626B1 (ko) 2007-01-04
EP1140964A4 (de) 2003-06-18
JP4722290B2 (ja) 2011-07-13
WO2000035936A1 (en) 2000-06-22
ATE391724T1 (de) 2008-04-15
AU2181900A (en) 2000-07-03
HK1041005B (zh) 2007-11-09
EP1140964B1 (de) 2008-04-09
AU773278B2 (en) 2004-05-20
JP4634614B2 (ja) 2011-02-16
WO2000035939A3 (en) 2000-10-12
CA2354456A1 (en) 2000-06-22
AU2004205171A1 (en) 2004-09-16
CN1334820A (zh) 2002-02-06
EP1140964A2 (de) 2001-10-10
AU3121100A (en) 2000-07-03
HK1041268B (zh) 2009-02-27
KR100664625B1 (ko) 2007-01-04
PT1140969E (pt) 2007-08-30
CN1660911A (zh) 2005-08-31
ES2304811T3 (es) 2008-10-16
JP2002532082A (ja) 2002-10-02
CY1108860T1 (el) 2014-07-02
HK1041268A1 (en) 2002-07-05
CA2354422A1 (en) 2000-06-22
DK1140969T3 (da) 2007-09-17
US7718177B2 (en) 2010-05-18
CN1170849C (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
HK1041005A1 (en) Connective tissue growth factor fragments and methods and uses thereof
CA2213533A1 (en) Resorbable extracellular matrix for reconstruction of cartilage tissue
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
FR2706767B1 (de)
CA2265508A1 (en) Bone morphogenetic protein-16 (bmp-16) compositions
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
ATE319812T1 (de) Knochen-vorläufer-zellen: zusammensetzungen und methoden
EP2228389A3 (de) Antikörper gegen vaskulären Endothelwachstumsfaktor 2
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
HK1104836A1 (en) Recombinant alpha-l-iduronidase and methods for treating diseases caused by deficiencies thereof
ATE269102T1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
ATE204174T1 (de) Verwendung von teilchen eines bioverträglichen und bioresorbierbaren kalziumsalzes als wirkstoff in der herstellung eines arzneimittels zur lokalen behandlung von entkalkungskrankheiten
EP1420031A3 (de) Morphogenetisches Protein der Knochen, BMP-18, und deren Zusammensetzungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
EP0832100A4 (de) Neuartige metalloprotease-inhibitoren, diese enthaltende pharmazeutische zusammensetzungen und anwendungsverfahren
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
ATE259652T1 (de) Neuronale verwendungen des bmp-11
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
TR200200278T2 (tr) Kalsilitik bileşimler
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
RO117234B1 (ro) Fibride colagenice şi procedeu de obţinere
MX9709908A (es) Compuestos cetoheterociclicos, uso de los mismos y composiciones que los contienen.
GEP19940075B (en) Method for Surgical Treatment of Low Prognathia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010716

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/475 B

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07K 14/00 B

Ipc: 7C 12P 21/06 B

Ipc: 7C 07H 21/04 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030606

17Q First examination report despatched

Effective date: 20030910

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69936315

Country of ref document: DE

Date of ref document: 20070726

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070820

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20070402316

Country of ref document: GR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VOSSIUS & PARTNER

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1041005

Country of ref document: HK

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2288321

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: VOSSIUS & PARTNER;NADELBERG 3;4051 BASEL (CH)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071214

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: UNIVERSITY OF MIAMI, US

Free format text: FORMER OWNER: UNIVERSITY OF MIAMI, US

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20181126

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20181210

Year of fee payment: 20

Ref country code: DK

Payment date: 20181211

Year of fee payment: 20

Ref country code: DE

Payment date: 20181204

Year of fee payment: 20

Ref country code: PT

Payment date: 20181213

Year of fee payment: 20

Ref country code: FI

Payment date: 20181210

Year of fee payment: 20

Ref country code: MC

Payment date: 20181212

Year of fee payment: 20

Ref country code: AT

Payment date: 20181126

Year of fee payment: 20

Ref country code: NL

Payment date: 20181213

Year of fee payment: 20

Ref country code: GR

Payment date: 20181212

Year of fee payment: 20

Ref country code: SE

Payment date: 20181211

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20181213

Year of fee payment: 20

Ref country code: GB

Payment date: 20181212

Year of fee payment: 20

Ref country code: CH

Payment date: 20181217

Year of fee payment: 20

Ref country code: BE

Payment date: 20181126

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20190102

Year of fee payment: 20

Ref country code: IT

Payment date: 20181220

Year of fee payment: 20

Ref country code: CY

Payment date: 20181206

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69936315

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20191214

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20191213

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20191213

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20191214

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191231

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191213

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 364617

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191214

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191215